Chair

Resolutions of the 2024 annual general meeting of Ørsted A/S

Retrieved on: 
Wednesday, March 13, 2024

Today, Ørsted A/S held its annual general meeting, where the following decisions were adopted:

Key Points: 
  • Today, Ørsted A/S held its annual general meeting, where the following decisions were adopted:
    The audited annual report for 2023 was approved.
  • In accordance with the proposal of the Board of Directors, no dividend is paid out to the shareholders for the financial year 2023.
  • The Board of Directors and the Executive Board were discharged from liability.
  • The proposed remuneration of the Board of Directors for 2024, which remains unchanged compared to the remuneration for 2023, was approved.

EQS-News: Linde Board Elects Paula Rosput Reynolds as New Director

Retrieved on: 
Wednesday, March 13, 2024

Woking, UK, February 27, 2024 – Linde plc (Nasdaq: LIN) announced today that its Board of Directors has elected Paula Rosput Reynolds as a new director of Linde plc, effective February 27, 2024.

Key Points: 
  • Woking, UK, February 27, 2024 – Linde plc (Nasdaq: LIN) announced today that its Board of Directors has elected Paula Rosput Reynolds as a new director of Linde plc, effective February 27, 2024.
  • Rosput Reynolds is a seasoned energy executive who brings substantial knowledge and global experience to the Linde plc Board of Directors.
  • Rosput Reynolds is currently Chair of National Grid plc and serves as a director at General Electric Company and senior independent director at BP plc.
  • "Paula has a distinguished track record of executive leadership and board service,” said Steve Angel, Chairman of Linde plc.

New Chair and Deputy Chair of Ørsted’s Board of Directors

Retrieved on: 
Wednesday, March 13, 2024

Ørsted’s Board of Directors recommends Lene Skole as new Chair and Andrew Brown as new Deputy Chair of the Board of Directors of Ørsted A/S.

Key Points: 
  • Ørsted’s Board of Directors recommends Lene Skole as new Chair and Andrew Brown as new Deputy Chair of the Board of Directors of Ørsted A/S.
  • On 7 February 2024, Ørsted announced that Thomas Thune Andersen, Chair of the Board of Directors of Ørsted A/S, decided not to seek re-election at the annual general meeting on 5 March 2024.
  • Based on this process, and when Thomas Thune Andersen informed the Board of Directors on 7 February 2024 of his decision to step down at the upcoming annual general meeting, the Board of Directors concluded that the best candidates for the positions as new Chair and Deputy Chair would be Lene Skole and Andrew Brown, respectively.
  • Lene Skole knows Ørsted very well, having served as Deputy Chair of Ørsted A/S since 2015.

Altus Group Nominates Thomas Warsop to its Board of Directors

Retrieved on: 
Thursday, March 7, 2024

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Altus Group Limited (ʺAltus Group” or the “Company”) (TSX: AIF), a leading provider of asset and fund intelligence for commercial real estate (“CRE”), announced today the nomination of Thomas Warsop (President and CEO of ACI Worldwide Inc.) to stand for election to its Board of Directors (the “Board”) at its upcoming annual general meeting of shareholders scheduled for May 1, 2024.

Key Points: 
  • TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Altus Group Limited (ʺAltus Group” or the “Company”) (TSX: AIF), a leading provider of asset and fund intelligence for commercial real estate (“CRE”), announced today the nomination of Thomas Warsop (President and CEO of ACI Worldwide Inc.) to stand for election to its Board of Directors (the “Board”) at its upcoming annual general meeting of shareholders scheduled for May 1, 2024.
  • “Tom Warsop is a seasoned technology executive with a proven track record of driving strategic change and growth in companies and sectors undergoing transformation,” said Raymond Mikulich, Chair of Altus Group’s Board of Directors.
  • He is an accomplished technology sector executive with over 30 years of experience, living and working around the world.
  • Throughout his career he has led portfolio companies for several leading private equity firms, including One Call Care Management, York Risk Services Group, and The Warranty Group.

CoreCivic Appoints Catherine Hernandez-Blades and Alexander R. Fischer to its Board of Directors; CoreCivic Also Announces Planned Retirement of Long-Term Board Member Donna Alvarado

Retrieved on: 
Thursday, March 7, 2024

Both Ms. Hernandez-Blades and Mr. Fischer are expected to join various board committees in the future.

Key Points: 
  • Both Ms. Hernandez-Blades and Mr. Fischer are expected to join various board committees in the future.
  • "We are pleased to have Catherine and Alex join our Board of Directors," said Damon Hininger, CoreCivic's President and Chief Executive Officer.
  • "Catherine brings decades of executive leadership experience in government relations, communications, and marketing in both the private and the public sectors.
  • Catherine also provides community support as a board member at several non-profits.

ACTG Presents Study at CROI Demonstrating Efficacy of Long-Acting Injectable Treatment Among People Who Had Previously Been Unable to Maintain Viral Suppression on Daily Oral Medication

Retrieved on: 
Wednesday, March 6, 2024

“ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

Key Points: 
  • “ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.
  • Participants received incentives and support to adhere to their daily oral medication to first achieve viral suppression and if successful, they were randomized to either receive long-acting injectable treatment every four weeks or continue taking daily oral medication.
  • The long-acting injectable treatment was more effective than the daily oral medication at maintaining virologic suppression and avoiding treatment-related discontinuation.
  • Twenty-eight participants receiving the long-acting injectable treatment experienced regimen failure (defined as virologic failure or treatment discontinuation), compared to 47 receiving daily oral medication.

Nominations Announced for the 2024 Canadian Screen Awards

Retrieved on: 
Wednesday, March 6, 2024

TORONTO, March 06, 2024 (GLOBE NEWSWIRE) -- Today, the Academy of Canadian Cinema & Television (the Canadian Academy) announced the nominees for the 2024 Canadian Screen Awards in 156 television, film, and digital media categories.

Key Points: 
  • TORONTO, March 06, 2024 (GLOBE NEWSWIRE) -- Today, the Academy of Canadian Cinema & Television (the Canadian Academy) announced the nominees for the 2024 Canadian Screen Awards in 156 television, film, and digital media categories.
  • The annual awards celebrating excellence on-screen will be presented over four days during Canadian Screen Week 2024, including The 2024 Canadian Screen Awards broadcast show, hosted by Mae Martin, airing on Friday, May 31 at 8 PM (9 AT, 9:30 NT) on CBC and CBC Gem.
  • The full schedule is as follows:
    The 2024 Canadian Screen Awards Box Office opens today, Wednesday, March 6, 2024.
  • For the full list of 2024 Canadian Screen Award nominees, please visit academy.ca/nominees ; view the full schedule for Canadian Screen Week 2024 at CanadianScreenWeek.ca .

FE International Appoints Chris Mayo to Chair New Advisory Board

Retrieved on: 
Wednesday, March 6, 2024

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Leading mergers and acquisitions advisory firm for technology businesses, FE International , announces the appointment of Chris Mayo as the Chair of its new Advisory Board.

Key Points: 
  • NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Leading mergers and acquisitions advisory firm for technology businesses, FE International , announces the appointment of Chris Mayo as the Chair of its new Advisory Board.
  • In this role, Chris will leverage his vast experience and industry knowledge to help guide the firm's development and deepen its network.
  • His appointment reflects FE International's commitment to clients in the tech sector.
  • “I am excited to work closely with the team, build out the new Advisory Board in my role as Chair and contribute to the firm's success in facilitating M&A transactions within the technology sector,” said Chris.

Nasdaq Outlines Strategy to Deliver Next Phase of Resilient and Scalable Growth

Retrieved on: 
Tuesday, March 5, 2024

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today will host its Investor Day at 8:00 AM ET, where Adena Friedman, Chair and CEO, Sarah Youngwood, Executive Vice President and CFO, and other members of the senior leadership team will detail the company’s plans to deliver its next phase of resilient and scalable growth.

Key Points: 
  • Additionally, the company will discuss its financial framework and capital allocation strategy as well as highlight the benefits of its divisional structure, unified with a One Nasdaq go-to-market approach.
  • “Nasdaq is the trusted fabric of the global financial system, providing market-leading platforms that enhance the liquidity, transparency, and integrity of the global economy.
  • Nasdaq will continue to successfully integrate Adenza to expand its growth opportunities, unlock synergies, and drive operating leverage.
  • The company will continue to accelerate the impact of its divisional structure and leverage its One Nasdaq strategy to create and deliver on new growth and revenue opportunities.

Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook

Retrieved on: 
Thursday, February 29, 2024

REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Gross profit, inclusive of grant and other revenue, was $2.0 million and gross margin was 45.1% for the fourth quarter of 2023.
  • Net loss was $17.8 million for the fourth quarter of 2023, as compared to $22.5 million for the corresponding prior year period.
  • Seer will host a conference call to discuss the fourth quarter and full year 2023 financial results on Thursday, February 29, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.